ALK and anaplastic large cell lymphoma: However, treatment-refractory ALK+ ALCL has a less positive outlook, with a median PFS and OS of 3.8 and 13.6 months, respectively, for patients with first-relapsed or refractory disease according to the LYSA study, which was before brentuximab vedotin56.